RECOMBINANT INTERLEUKIN-2 TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL-CANCER - EFFECT ON NATURAL CYTOTOXICITY

被引：11

作者：

PARK, KGM ^{[1
]}

HEYS, SD ^{[1
]}

MURRAY, JB ^{[1
]}

HAYES, PD ^{[1
]}

ASHBY, JA ^{[1
]}

FRANKS, CR ^{[1
]}

EREMIN, O ^{[1
]}

机构：

[1] EUROCETUS BV,1105J AMSTERDAM,NETHERLANDS

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1992年 / 35卷 / 01期

关键词：

INTERLEUKIN-2; COLORECTAL CANCER; NATURAL CYTOTOXICITY; CYTOTOXICITY;

D O I：

10.1007/BF01741055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1 +/- 6.9%, mean +/- SD; posttreatment: 39.2 +/- 6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

引用

页码：53 / 58

页数：6

共 50 条

[31] Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer
Douillard, JY
Bennouna, J
Vavasseur, F
Deporte-Fety, R
Thomare, P
Giacalone, F
Meflah, K
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (01) : 56 - 61
[32] Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
Lindnér, P
Rizell, M
Mattsson, J
Hellstrand, K
Naredi, P
ANTICANCER RESEARCH, 2004, 24 (3B) : 1837 - 1842
[33] Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer
Shibata, M
Takekawa, M
ONCOLOGY, 1999, 56 (01) : 54 - 58
[34] Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
Kammula, US
White, DE
Rosenberg, SA
CANCER, 1998, 83 (04) : 797 - 805
[35] Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer
Quan, Walter D. Y., Jr.
Vinogradov, Mikhail
Quan, Francine M.
Khan, Nawazish
Liles, Darla K.
Walker, Paul R.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (05) : 515 - 519
[36] Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer
Walker, PR
Khuder, SA
Quan, WDY
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (05) : 487 - 490
[37] Time course of the cytotoxicity of blood mononuclears in patients with bladder cancer during endolymphatic immunotherapy with lymphokine-activated killers and recombinant interleukin-2
Malakhova, NV
Figurin, KM
Fedorova, NS
Kiselevskii, MV
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1996, 121 (02) : 174 - 177
[38] LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND LOW-DOSE CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER
SPICER, DV
KELLEY, A
HERMAN, R
DEAN, G
STEVENSON, L
MITCHELL, MS
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (06) : 424 - 426
[39] INTERLEUKIN-2 THERAPY IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
DORVAL, T
FRIDMAN, WH
MATHIOT, C
SASTRE, X
POUILLART, P
BULLETIN DU CANCER, 1992, 79 (08) : 781 - 787
[40] Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2:: an outcome study
Huland, E
Burger, A
Fleischer, J
Fornara, P
Hatzmann, E
Heidenreich, A
Heinzer, H
Heynemann, H
Hoffmann, L
Hofmann, R
Huland, H
Kämpfer, I
Kindler, M
Kirchner, H
Mehlhorn, G
Moniak, TH
Rebmann, U
Roigas, J
Schneider, TH
Schnorr, D
Schmitz, HJ
Wenisch, R
Varga, Z
Vinke, J
FOLIA BIOLOGICA, 2003, 49 (05) : 183 - 190

← 1 2 3 4 5 →